EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability–High Advanced Gastric or Esophagogastric Junction Cancer

Hisato Kawakami iD, Shigenori Kadowaki iD, Akitaka Makiyama iD, Masahiro Tsuda, Kenro Hirata, Naotoshi Sugimoto, Nozomu Machida iD, Hiroki Hara iD, Hidekazu Hirano iD, Taito Esaki iD, Yoshito Komatsu iD, Shuichi Hironaka iD und 6 weitere

Journal of Clinical Oncology · 2025-07 · 43 (19) · 2184-2195

DOI: 10.1200/jco-24-02463 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, 2025-07. Verfasst von Hisato Kawakami und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-sayama, Japan. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Esophageal Neoplasms, Esophagogastric Junction, Ipilimumab. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Microsatellite instability–high (MSI-H) advanced gastric or esophagogastric junction cancer (AGC), accounting for 5%-6% of all AGC cases, has shown an enhanced responsiveness to immunotherapy. We performed a single-arm phase II study to evaluate the combination of nivolumab (NIVO) and low-dose (LD) ipilimumab (IPI) for first-line treatment of MSI-H AGC. PATIENTS AND METHODS Patients with MSI-H AGC received NIVO (240 mg once every 2 weeks) and IPI (1 mg/kg once every 6 weeks). The primary end point was overall response rate (ORR) assessed by blinded independent central review. Secondary end points included disease control rate (DCR), progression-free survival (PFS), overall survival (OS), safety, and biomarker analysis. MSI-H status was confirmed with an MSI-IVD Kit (Falco). RESULTS Twenty-nine patients were enrolled. The ORR was 62.1% (95% CI, 42.3 to 79.3), with a complete response rate of 10.3%. The DCR was 79.3% (95% CI, 60.3 to 92.0). Treatment-related adverse events (TRAEs) of any grade occurred in 93.1% of patients, with those of grade ≥3 manifesting in 37.9% of patients. At the data cutoff (median follow-up of 9.0 months), treatment had been discontinued in 21 patients, with such discontinuation being due to TRAEs in 12 (41.4%) patients. However, after exclusion of one patient with progressive disease, the remaining 11 patients showed long-term antitumor efficacy after treatment discontinuation (range of response duration, 0.9+ to 15.6+ months). The median PFS was 13.8 months (95% CI, 13.7 months to not reached [NR]) and the median OS was NR (95% CI, 13.7 months to NR), with a 12-month OS rate of 79.5%. CONCLUSION NIVO plus LD-IPI showed robust and durable antitumor efficacy as a first-line treatment for MSI-H AGC. Although TRAEs often led to treatment discontinuation, treatment efficacy was subsequently sustained in most patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsEsophageal NeoplasmsEsophagogastric JunctionIpilimumabMicrosatellite InstabilityStomach NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedNivolumabProgression-Free Survival

Substanzen

IpilimumabNivolumab

Autor:innen und Institutionen

  • Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-sayama, Japan.
  • Department of Clinical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Cancer Center, Gifu University Hospital, Gifu, Japan.
  • Center for One Medicine Innovative Translational Research, Gifu University, Gifu, Japan.
  • Department of Gastroenterological Oncology, Hyogo Cancer Center, Akashi, Japan.

ORCID-Profile: Hisato Kawakami, Shigenori Kadowaki, Akitaka Makiyama, Nozomu Machida, Hiroki Hara, Hidekazu Hirano, Taito Esaki, Yoshito Komatsu, Shuichi Hironaka, Yukari Kobayashi, Narikazu Boku, Ichinosuke Hyodo

Zitieren

APA

Kawakami, H., Kadowaki, S., Makiyama, A., Tsuda, M., Hirata, K., Sugimoto, N., Machida, N., Hara, H., Hirano, H., Esaki, T., Komatsu, Y., Hironaka, S., Kobayashi, Y., Kakimi, K., Chiba, Y., Boku, N., Hyodo, I., & Muro, K. (2025). Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability–High Advanced Gastric or Esophagogastric Junction Cancer. Journal of Clinical Oncology, 43(19), 2184-2195. https://doi.org/10.1200/jco-24-02463

Vancouver

Kawakami H, Kadowaki S, Makiyama A, Tsuda M, Hirata K, Sugimoto N, et al. Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability–High Advanced Gastric or Esophagogastric Junction Cancer. Journal of Clinical Oncology. 2025;43(19):2184-2195. doi:10.1200/jco-24-02463

BibTeX
@article{Kawakami2025,
  author = {Kawakami, Hisato and Kadowaki, Shigenori and Makiyama, Akitaka and Tsuda, Masahiro and Hirata, Kenro and Sugimoto, Naotoshi and Machida, Nozomu and Hara, Hiroki and Hirano, Hidekazu and Esaki, Taito and Komatsu, Yoshito and Hironaka, Shuichi and Kobayashi, Yukari and Kakimi, Kazuhiro and Chiba, Yasutaka and Boku, Narikazu and Hyodo, Ichinosuke and Muro, Kei},
  title = {Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability–High Advanced Gastric or Esophagogastric Junction Cancer},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {19},
  pages = {2184--2195},
  doi = {10.1200/jco-24-02463}
}
Kostenlos starten →